Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index; 1 of the 6 sources its claims cite were checked for support.
Abstract
BACKGROUND: Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of transplantation-eligible patients with newly diagnosed multiple myeloma is needed. METHODS: In this phase 3 trial, we randomly assigned 709 transplantation-eligible patients with newly diagnosed multiple myeloma to receive either subcutaneous daratumumab combined with VRd induction and consolidation therapy and with lenalidomide maintenance therapy (D-VRd group) or VRd induction and consolidation therapy and lenalidomide maintenance therapy alone (VRd group). The primary end point was progression-free survival. Key secondary end points were a complete response or better and minimal residual disease (MRD)-negative status. RESULTS: At a median follow-up of 47.5 months, the risk of disease progression or death in the D-VRd group was lower than the risk in the VRd group. The estimated percentage of patients with progression-free survival at 48 months was 84.3% in the D-VRd group and 67.7% in the VRd group (hazard ratio for disease progression or death, 0.42; 95% confidence interval, 0.30 to 0.59; P<0.001); the P value crossed the prespecified stopping boundary (P = 0.0126). The percentage of patients with a complete response or better was higher in the D-VRd group than in the VRd group (87.9% vs. 70.1%, P<0.001), as was the percentage of patients with MRD-negative status (75.2% vs. 47.5%, P<0.001). Death occurred in 34 patients in the D-VRd group and 44 patients in the VRd group. Grade 3 or 4 adverse events occurred in most patients in both groups; the most common were neutropenia (62.1% with D-VRd and 51.0% with VRd) and thrombocytopenia (29.1% and 17.3%, respectively). Serious adverse events occurred in 57.0% of the patients in the D-VRd group and 49.3% of those in the VRd group. CONCLUSIONS: The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy conferred a significant benefit with respect to progression-free survival among transplantation-eligible patients with newly diagnosed multiple myeloma. (Funded by the European Myeloma Network in collaboration with Janssen Research and Development; PERSEUS ClinicalTrials.gov number, NCT03710603; EudraCT number, 2018-002992-16.).
Overview
CoChat Summary
## TL;DR
The supplementary appendix for the PERSEUS trial describes a randomized comparison of subcutaneous daratumumab plus bortezomib/lenalidomide/dexamethasone (D-VRd) versus VRd alone in transplant-eligible patients with newly diagnosed multiple myeloma. It mainly provides endpoint definitions, statistical methods, eligibility criteria, subgroup results, and safety tables, but not the full primary efficacy narrative.
## Key findings
- The trial’s primary endpoint was progression-free survival; key secondary endpoints were overall complete response or better, overall minimal residual disease (MRD)-negativity, and overall survival.
- At the interim analysis, the primary endpoint was tested at an exact two-sided significance level of 0.0126, determined by 153 progression-free survival events under an Hwang-Shih-DeCani alpha-spending function.
- In prespecified subgroup analyses, D-VRd showed higher overall complete response or better rates and MRD-negativity rates across most reported subgroups; for example, MRD-negativity was 71.1% vs 45.9% in men, 81.3% vs 49.7% in women, and 78.2% vs 46.8% in patients younger than 65 years.
- Safety tables report serious adverse events in 57.0% of D-VRd patients (200/351) versus 49.3% of VRd patients (171/347); infections were the most common serious adverse event category (35.0% vs 27.4%).
## Methods
- Randomized PERSEUS study in transplant-eligible patients with newly diagnosed multiple myeloma; eligible patients were 18 to 70 years old and had ECOG performance status 0 to 2 and specified laboratory/organ-function criteria.
- The appendix specifies an intention-to-treat framework for efficacy endpoints and a safety population of patients who received at least one dose of study treatment; sample sizes in the safety tables were 351 for D-VRd and 347 for VRd.
- Main analyses included progression-free survival with two interim analyses and a final analysis, plus hierarchical testing of key secondary endpoints to control family-wise type I error; subgroup analyses are shown for complete response or better and MRD-negativity.
## Limitations
- The appendix text itself does not report the main trial’s headline efficacy results (for example, hazard ratios or median progression-free survival), so those outcomes cannot be summarized from this text alone.
- The subgroup forest plots note that the widths of confidence intervals were not adjusted for multiplicity and cannot be used to infer treatment effects.
- Evident from the provided text: this is a supplementary appendix only, so it is incomplete as a standalone paper summary.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
1 Valid · 1 Not valid · 3 Not checked · 42 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| Standard risk | 182/266 (68.4) | 234/264 (88.6) | | 3.60 (2.27–5.70) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| Non-IgG | 73/96 (76.0) | 72/78 (92.3) | | 3.78 (1.45–9.83) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| ≥65 years | 62/87 (71.3) | 77/94 (81.9) | | 1.83 (0.91–3.68) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Male | 94/205 (45.9) | 150/211 (71.1) | | 2.90 (1.94–4.35) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| <65 years | 186/267 (69.7) | 235/261 (90.0) | | 3.94 (2.43–6.37) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
24 more claims
Create a free account to see all 47 claims and every source verdict.
- Probably not a substantial claim. 10
- It may state two separate claims as one. 11
- The quote only partly states this claim. 3
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The quadruplet regimen of daratumumab, bortezomib, lenalidomide, and dexamethasone (Dara-VRd) has recently emerged as standard of care option for initial therapy in transplant eligible patients with newly diagnosed myeloma.101,111”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [101]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The role of daratumumab in patients who received it as part of frontline therapy is unclear.101,152”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [101]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Daratumumab, an anti-CD38–targeting monoclonal antibody (mAb), is a cornerstone of standard-of-care MM regimens with demonstrated survival benefit across all lines.9–14”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [9]
Experimental — accuracy not yet measured
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationKumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationLenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257
Self-citationde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationMoreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Broijl, A., Caillon, H., Caillot, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31240-1 · Cited by 967
Self-citationKrejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B., Bald, J., Plesner, T., Syed, K., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., et al. (2016) · Blood · doi:10.1182/blood-2015-12-687749 · Cited by 954
Self-citationMultiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationGlobal Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016
Cowan, A. J., Allen, C., Barac, A., Basaleem, H., Bensenor, I., Curado, M. P., Foreman, K., Gupta, R., Harvey, J., Hosgood, H. D., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2128 · Cited by 631
Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521
Research works printed but not linked: 1
- 7. Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol 2016;43:676-81.
Cited by
Items 301–400 of 589
Li, X., Xu, X., Lai, X., Wang, X., Liu, X., Liu, X., Wang, L., Sheng, Z., Peng, J., Chen, P., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.71353 · Cited by 1
“Recent studies have established and further consolidated triplet and qua-druplet regimens in the management of MM patients [39–42].”
Guadagno, L., Schütt, J., Brinkert, K., Schenk, T., & Brioli, A. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2575438 · Cited by 3
“…of MM has undergone a profound change in the last two decades [6–14], translating in an increased progression free and overall survival for MM patients with an estimated progression free survival for patients diagnosed with MM in 2025 that is estimated to be between ten and fifteen years [11,15].”
Sáez, A., Hernandez-Ibarbu, G., de Alba, L. M., Babio, R. M., Tamayo, A., Fonseca, A. C., Sánchez‐Pina, J. M., Fernández, R. A. A., López‐Muñoz, N., Sánchez, A. B., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.10.021 · Cited by 1
Lim, S., Wellard, C. J., Rajagopal, R., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.70238 · Cited by 1
Self-citationIriyama, N., Nakayama, H., Nakagawa, M., Takahata, A., Sato, E., Takano, M., Okada, K., Toyama, K., Hayashi, T., Abe, T., et al. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-04100-2 · Cited by 1
Jimenez-Zepeda, V. H., Cheung, W. Y., Stephen, M. M., & Chan, H. S. H. (2025) · Future Oncology · doi:10.1080/14796694.2025.2589058 · Cited by 1
Yoshida, M., Murase, K., Suzuki, N., et al. (2025) · BMJ Supportive & Palliative Care · doi:10.1136/spcare-2025-005814 · Cited by 1
Lin, J., He, J., Cai, Z., & He, D. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2596804 · Cited by 1
“Furthermore, the phase 3 PeRSeUS trial [15], the BeNeFit trial [16], the iskia trial [17] and the iMROZ trial [18] collectively demonstrated that patients achieving higher rates of MRD negativity have a strong positive correlation with significantly prolonged overall survival.”
Transplant in myeloma: what is its role?
Valdes, C. R. (2025) · Hematology · doi:10.1182/hematology.2025000730 · Cited by 1
What is the best induction for myeloma for the fit patient?
Shah, N. N., & Kaufman, J. L. (2025) · Hematology · doi:10.1182/hematology.2025000731 · Cited by 1
How to approach the high-risk myeloma from induction through relapse?
Weisel, K. C., Schaefers, C., & Leypoldt, L. B. (2025) · Hematology · doi:10.1182/hematology.2025000762 · Cited by 1
Pasvolsky, O., Marcoux, C., Milton, D. R., Haider, A. A., Tanner, M. R., Bashir, Q., Srour, S. A., Saini, N. Y., Smallbone, P., Lin, P., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02771-3 · Cited by 3
Liu, Y., Zhang, Y., Yang, W., Du, H., Sun, S., Li, Z., & Zong, D. (2025) · Pharmaceuticals · doi:10.3390/ph19010018 · Cited by 1
Self-citationMRD Directed Consolidation in Multiple Myeloma—Are We There Yet?
Mirgh, S. P., Sood, K., Punatar, S. B., Gokarn, A. G., Chichra, A., Nayak, L., Bain, G. G., Bagal, B. P., & Khattry, N. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.017 · Cited by 1
First-line Therapy in Newly Diagnosed Multiple Myeloma
Miller, K. C., & Usmani, S. Z. (2026) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-25-0384 · Cited by 2
Feng, A., Wu, J., Choi, T., Wang, X., Bellavia, T., Burcher, K. M., Jones, L., Schrum, D. P., Eberwein, E., Cheng, S., et al. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.02.009 · Cited by 1
Smith, E., Camera, A., & Bird, A. (2026) · Oncology and Therapy · doi:10.1007/s40487-026-00419-w · Cited by 1
Challenges and Potential Solutions to Advance Global Cancer Drug Development
Glasmacher, A., Lyerly, H. K., Wolf, B., Zapella, P. D. A., Zielińska, L., Clark, E., Mauer, M. E. L., Paiva, B., Schiel, A. E., Sweeney, F., et al. (2026) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-026-00936-w · Cited by 2
Gahvari, Z. J., & Callander, N. S. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.03.005 · Cited by 1
MajesTEC-3: Redefining what’s possible in multiple myeloma
Hadidi, S. A., & Gaballa, M. (2026) · Clinical Hematology International · doi:10.46989/001c.158751 · Cited by 1
On-target, off-tumor oral toxicities of talquetamab in heavily pretreated multiple myeloma
Alves, F. A., Perez, A. P., Jaguar, G. C., Filho, J. S., Kim, M. H. (., & Villa, A. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-10583-4 · Cited by 1
Hong, Z., Wu, Y., Liu, W., Li, D., & Xu, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1773233 · Cited by 3
Xie, Z., Qin, Y., Xue, X. M., Chen, X., Xie, T., Zhu, H., Huang, L., Yang, S., Yang, J., Liu, P., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025018014 · Cited by 1
“19,60,61 Considering that bortezomib-based regimens have shown promising efficacy in multiple myeloma and PBL, both of which are terminally differentiated plasma cell neoplasms, 5,62-64 we wondered whether DLBCL with plasma cell–like phenotype may also benefit from bortezomib-containing therapies.”
Gozzetti, A., Pacelli, P., Caroni, F., Raspadori, D., Bestoso, E., Antonioli, E., Buda, G., Ciofini, S., Santoni, A., Puccetti, L., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70448 · Cited by 1
“32 Moreover, sustained MRD negativity rate at 12 months was superior with D-VRd versus VRd (64.8% vs. 29.7%; p = 0.0001), and MRD negativity rate at 10 −6 was significantly increased in the D-VRd group versus the VRd group (65.1% vs. 32.2%; p = 0.0001).”
InfluentialSelf-citationZhou, X., Liu, Y., Zhang, P., & Shan, N. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178812 · Cited by 1
Self-citationHAT ‐ PCR is non‐inferior to NGS when quantifying measurable residual disease for myeloma
Hughes, E., Blombery, P. A., Kannan, S., Khong, T. T., Spencer, A. G., & Morley, A. A. (2026) · British Journal of Haematology · doi:10.1111/bjh.70478 · Cited by 1
Self-citationHow Laboratory Innovations Are Shaping the Future of Multiple Myeloma Care
Caetano, J., Pires, A. M., Costa, C. M. A., Bergantim, R., Roque, A. I., Ferraz, P., Cunha, M. R., Bolli, N., Puig, N., & Joao, C. M. (2026) · Cancers · doi:10.3390/cancers18081275 · Cited by 1
Barbieri, E., Arletti, L., Quaresima, M., Rivolti, E., Braglia, L., Fabiano, C., Alfano, A. M. R., Rinaldini, M., Bizzarri, V., Cattani, C., et al. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70198 · Cited by 1
“Indeed, CASSIOPEIA [18, 19], ALCYONE [20, 21], POLLUX [22, 23], CASTOR [24, 25], CANDOR [26, 27], APOLLO [28, 29] and, more recently, PERSEUS [30] did not provide +1q-focused results.”
Chari, A., Costello, C. L., Krishnan, A. Y., Patel, K. K., Banerjee, R. K., Berdeja, J. G., Biran, N., Callander, N. S., Costa, L. J., Dhakal, B., et al. (2026) · American Journal of Hematology · doi:10.1002/ajh.70339 · Cited by 4
“Indeed in the PERSEUS study, although the addition of daratumumab improved PFS over VRD alone, both the quadruplet and triplet containing arms received ASCT [28].”
Goel, U., Dragomirescu, C., Zanwar, S., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70490 · Cited by 1
Awadallah, C., Zayad, A., Atrash, S., Mazloom, A., Alkharabsheh, O. A., Mewawalla, P., Shah, M. R., Lutfi, F. U., Mahmoudjafari, Z., Mushtaq, M. U., et al. (2026) · Current Oncology · doi:10.3390/curroncol33050249 · Cited by 1
“Anti-CD38-containing frontline regimens were absent before 2020 but were used in 26.6% of patients in Era 3 ( p 0.001), driven by the adoption of daratumumab-based quadruplets following the GRIFFIN and PERSEUS trials [10,23].”
InfluentialLeveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma
Ren, Z., Zhao, Z., Cowan, A. J., Ma, W., Xie, E., & Shi, Q. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0393 · Cited by 2
Xie, W., Zhang, L., Yue, C., Wang, B., Guo, S., Lian, X., & Zhang, C. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1783651 · Cited by 1
PKMYT1 is a targetable vulnerability in del(17p) high-risk multiple myeloma
Schavgoulidze, A., Cui, J., Encinas, J., et al. (2026) · Blood · doi:10.1182/blood.2026033819 · Cited by 1
Five trials reshaping multiple myeloma
Talbot, A., Bobin, A., Touzeau, C., Arnulf, B., Manier, S., Perrot, A., & Leleu, X. P. (2026) · Med · doi:10.1016/j.medj.2026.101177 · Cited by 1
Self-citationNSD2 degradation remediates the oncogenic cistrome in t(4;14) multiple myeloma
Hu, B., Edwards, J. T., Modi, H., Gamez, J., Echeagaray, O. E., Hess, K. N., Ren, Y., Anderson, D., Larráyoz, M., Zhu, J., et al. (2026) · Blood · doi:10.1182/blood.2025031998 · Cited by 1
Iftikhar, R., Ghani, D. A., Sarwar, S., Ali, N., Anwar, N., Bokhari, S. W., Humayun, S., Iftikhar, A., Moosajee, M., Zaidi, U., et al. (2026) · Blood Global Hematology · doi:10.1016/j.bglo.2026.100121 · Cited by 1
Time to Stop? Rethinking the Duration of Maintenance Treatment in Multiple Myeloma
Mian, H. S., & Costa, L. J. (2026) · New England Journal of Medicine · doi:10.1056/nejme2604761 · Cited by 1
Ravi, G., Dhakal, B., Callander, N. S., Medvedova, E., Dholaria, B., Godby, K. N., Bal, S., Huls, F., Silbermann, R. W., & Costa, L. J. (2026) · Cancer · doi:10.1002/cncr.70478 · Cited by 1
“18 Although R2 - ISS stage, IMS/IMWG high - risk status, and the presence of one or multiple high - risk chromosome abnormalities are predictors of progression in the setting of QUAD + ASCT, they fail to capture all early relapses.”
InfluentialMinakata, D., Yamamoto, G., Kako, S., Hiroshima, Y., Ota, S., Handa, T., Wake, A., Meguro, A., Usuki, K., Tsukada, N., et al. (2026) · Blood Research · doi:10.1007/s44313-026-00154-1 · Cited by 1
“Recent quadruplet induction studies, such as PERSEUS and GMMG-HD7 [5, 8], have also demonstrated highly favorable outcomes in trans-plant-eligible patients with NDMM, although OS data are not yet mature.”
Joy, A., Philip, A., Muralikrishnan, R., Niraimathi, K., Zachariah, R., Thekkur, P., Doshi, A., Arya, M. P., Ajith, K., Hari, V., et al. (2026) · Public Health Action · doi:10.5588/pha.26.0046 · Cited by 1
“Increasing access to daratumumab (CD38 monoclonal antibody) during induction may improve progression-free survival, 26,27 but cost is a major barrier (approximately USD 40,000 per year only for the drug).”
Stino, A. M., & Becker, B. E. (2026) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/cont.0000000000001748 · Cited by 1
MINT trial signals potential benefit of liberal transfusion strategy in MI with anaemia
Fernández-Ruíz, I. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00969-w · Cited by 1
Mori, Y., Takizawa, J., Katsuoka, Y., Takezako, N., Nagafuji, K., Handa, H., Kuroda, J., Sunami, K., Kamimura, T., Ogawa, R., et al. (2024) · Cancer Science · doi:10.1111/cas.16158
Mohyuddin, G. R., & Goodman, A. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00895-x · Cited by 1
“…previous trials involving patients with newly diagnosed multiple myeloma (NDMM) were designed in a way that precludes evaluation of the therapeutic value of the drug in the maintenance versus induction period and, as a result, expensive and toxic long-term maintenance therapy remains pervasive 2 .”
Callander, N. S. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00097-8 · Cited by 1
Daratumumab maintenance in patients with myeloma
Beksaç, M. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00341-3 · Cited by 1
Self-citation(2024) · EMJ Hematology · doi:10.33590/emjhematol/umdh9964 · Cited by 1
Parchinski, K., Urquhart-Foster, K., Purser, S. A., et al. (2024) · Current Problems in Cancer Case Reports · doi:10.1016/j.cpccr.2024.100316 · Cited by 1
García, A. P., Ruiz, E., Moreno, M. J., Español, I., Sánchez‐Salinas, A., García-Hernández, A. M., Blanquer, M., Martínez, I., Sánchez‐Villalobos, M., Garay, M. C. G., et al. (2024) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02404-1 · Cited by 1
“Quadruplet therapy, as demonstrated in the GRIFFIN, PERSEUS, and CASSIOPEIA clinical trials, and supported by real-word evidence, may improve patient prognosis without tandem ASCT approach [6 – 9].”
Amsterdam, D., Grossberger, O., Melamed, N., Shpitzer, D., Trestman, S., Shragai, T., Cohen, Y. C., & Avivi, I. M. (2024) · Cancers · doi:10.3390/cancers16193329 · Cited by 1
Actualités 2024 par le Comité de rédaction du Bulletin du cancer : congrès ASCO, ESMO et au-delà
Vignot, S., Bellesœur, A., Bouleuc, C., Cohen, R., Courtier, B., Crozier, C., de Nonneville, A. T., Delom, F., Évrard, S., Firmin, N., et al. (2024) · Bulletin du Cancer · doi:10.1016/j.bulcan.2024.12.001 · Cited by 1
Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
Galušić, D., Krečak, I., Blaslov, V., Anđela, K. O., Valković, T., & Bašić‐Kinda, S. (2025) · Biomedicines · doi:10.3390/biomedicines13010207 · Cited by 1
Daratumumab for maintenance in myeloma
Touzeau, C., & Perrot, A. (2025) · Blood · doi:10.1182/blood.2024026888 · Cited by 1
Self-citationRosenberg, A. S., Maverakis, E., Costello, C. L., Brem, E. A., Wieduwilt, M. J., Luxardi, G., Kaesberg, P. R., Abedi, K., Herbert, S. M., & Tuscano, J. M. (2025) · Blood Neoplasia · doi:10.1016/j.bneo.2025.100067 · Cited by 2
Wang, Y.-C., Lin, C., Su, Y., & Teng, C. J. (2025) · Hematology · doi:10.1080/16078454.2025.2462249 · Cited by 5
“Notably, compared to quadruplet induction using daratumumab and VRD [3], hematological AEs seemed substantially lower in the VTD approach.”
Beechinor, R. J., Lam, S., Steele, A. P., Wilson, M., Fine, J., Ullah, A., & Rosenberg, A. S. (2025) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2025.02.001 · Cited by 1
Pasvolsky, O., Abid, M. B., Milton, D. R., Tanner, M. R., Bashir, Q., Srour, S. A., Saini, N. Y., Jatoi, A., Khan, H., Lin, P. Y., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.20062 · Cited by 2
Quezada-Ramírez, S. I., Tarin-Arzaga, L. C., León, A. G., & Gómez‐Almaguer, D. (2025) · Expert Review of Hematology · doi:10.1080/17474086.2025.2490764 · Cited by 2
“Both trials followed a similar methodology, however, the phase 3 PERSEUS trial had a more robust patient sample [21,22].”
Brummer, C., Utpatel, K., Geis, S., Haferkamp, S., Brosig, A. M., Herrmann, M., Arnreich, C., Hahn, J., Pukrop, T., Herr, W., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06366-2 · Cited by 1
Liu, Y., Desai, P. M., Nadeem, O., Woyach, J. A., & Alsouqi, A. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473650 · Cited by 3
Self-citationLandgren, O., Biran, N., O’Donnell, E., Mikhael, J. R., Weisel, K. C., Broijl, A., Usmani, S. Z., Moreau, P., Gay, F., Mina, R., et al. (2025) · HemaSphere · doi:10.1002/hem3.70178 · Cited by 1
“Phase 3 studies of VRd with or without isatuximab 12 or daratumumab 13 have demonstrated additional benefit to adding the anti ‐ CD38 mAb inTe NDMM. Quadruplet induction therapy is now a key recommendation across guidelines for Te NDMM, 14,15 and quadruplet use in NDMM treatment continues to rise.”
Self-citationFokkema, C., Appelman, M. K., Veldhoen, N., Spelt, A., van der Holt, B., Grootes, M., Wester, R., de Pater, E., Ypma, P. F., Broers, A. E. C., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02681-4 · Cited by 3
“The addition of daratumumab to the induction regimen has improved the progression free survival of TE-NDMM and is now standard of care [1, 8].”
Self-citationAktuelle Fortschritte und neue Therapieoptionen in der Immunonkologie
Kobold, S., & Müller, R. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2502-1305 · Cited by 1
Investigating CAR-T Treatment Access for Multiple Myeloma Patients Using Real-World EvidencePreprint
Davidson, J., Kumar, A. D., Patel, A. R., et al. (2025) · medRxiv · doi:10.1101/2025.04.16.25325784 · Cited by 1
Cilta-cel salvages ide-cel failure in relapsed multiple myeloma by driving distinct immune responsesPreprint
Pan, T., Tang, E., Hu, Y., Asby, N. W., Schubat, M., Althaus, T., Riedell, P. A., Derman, B. A., & Huang, J. (2025) · medRxiv · doi:10.1101/2025.07.10.25331322 · Cited by 1
“While modern myeloma treatment regimens have yielded improved response rates and progression-free survival durations 2–4 , most patients eventually relapse or become refractory to treatment.”
A Cure, a Cure, My Kingdom for a Cure…
Lonial, S., & Kumar, S. K. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-01258 · Cited by 1
Abelman, D. D., Eagles, J., Wong, A., Shah, S., Bruce, J. P., Pedersen, S., Scott, D. S., de Campos, C. B., Chow, S., Wei, E. N., et al. (2025) · medRxiv · doi:10.1101/2025.10.24.25338566 · Cited by 2
PERSEUS triumphs — efficacy of daratumumab confirmed in transplant-eligible NDMM
Killock, D. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00856-w
New standard of care for multiple myeloma?
Nierengarten, M. B. (2024) · Cancer · doi:10.1002/cncr.35296
Treg depletion supercharges ASCT power
Bruns, H. (2024) · Blood · doi:10.1182/blood.2024024075
„Tsunami der Immuntherapie eröffnet neue therapeutische Möglichkeiten beim Multiplen Myelom“
(2024) · best practice onkologie · doi:10.1007/s11654-024-00575-3
Saba, L., Fu, C., Liang, H., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4830035
Extended DaraKRd: Are we enhancing outcomes by prolonging treatment?
Schmidt, T. M. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01070-2
“In fact, despite excellent response rates, elderly patients have often experienced less long-term bene fi t from PI-based regimens, as noted in S0777 [2], PERSEUS [3], and particularly the GEM2017FIT trial, which showed higher mortality rates for patients aged 65-80 who were treated with DaraKRd [4].”
BackgroundJiwani, R. A., Liput, J., Abraham, A., Alhamad, K., Kapdi, M., Mota, R. A., Forte, K., McGill, J. R., Acer, J. C., Nisarga, P., et al. (2024) · Journal of Hematology · doi:10.14740/jh1248
“The addition of anti-CD38 monoclonal antibodies to standard triplet regimens has become the standard of care for high-risk transplant eligible MM patients [7].”
BackgroundIsatuximab plus carfilzomib–dexamethasone for relapsed multiple myeloma
Maruyama, D., & Yamauchi, N. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00220-5
Risk‐adapted treatment in multiple myeloma: Does more make it merrier?
Zanwar, S., Fortuna, G. G., & Sborov, D. W. (2024) · British Journal of Haematology · doi:10.1111/bjh.19676
Chung, A., Kumar, A. D., & Chari, A. (2024) · The Hematologist · doi:10.1182/hem.v21.5.202457
Steinhardt, M., Kortüm, K. M., & Einsele, H. (2024) · Trillium Krebsmedizin · doi:10.47184/tk.2024.04.6
Self-citationThe Role of Maintenance Therapy in the Treatment of Newly Diagnosed Multiple Myeloma
Gahvari, Z. J., & Callander, N. S. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(24)00344-6
Not so natural, not so killers
Paiva, B., & Martinez-Climent, J. A. (2024) · Blood · doi:10.1182/blood.2024025597
High-Risk Myeloma: Definitions and Treatments
Sharma, R., Sanchez-Hernandez, K. A., & Lancman, G. (2024) · Canadian Hematology Today · doi:10.58931/cht.2024.3254
Bal, S., Magnusson, T., Ravi, G., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5015478/v1
MIELOMA MÚLTIPLO: UM SOPRO DE ESPERANÇA COM A TERAPIA QUÁDRUPLA
Rodrigues, L. L. L. F., & da Silva, A. J. (2024) · Revista Multidisciplinar do Nordeste Mineiro · doi:10.61164/rmnm.v12i3.3170
Chougule, D., Aggarwal, G., Sood, N., et al. (2024) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-024-01914-8
Wei, X., Wang, Y., Zhang, L., Dong, H., Chen, H., Zhang, H., Yuan, Y., Zhang, C., Feng, R., & Wei, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-5411786/v1
Expert Opinion on Multiple Myeloma Treatment in Brazil in the Bispecific Antibody Era
Hungria, V., Neto, J. V. P., Garibaldi, P. M. M., Jansen, A. M., Filho, R. J. P. D. M., Pericole, F. V., Sanku, G., & Maiolino, Â. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.12.001 · Cited by 1
Williams, A. K., & Doucette, K. (2024) · Springer eBooks · doi:10.1007/978-3-031-75810-2_11
Qiao, S., Song, Y. S., Dong, X., Chen, X., Meng, H., Long, H., Gong, J., Wang, Y., Liu, Y., Liu, Y., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5075166
Self-citationKumar, A. D., Chung, A., & Chari, A. (2025) · The Hematologist · doi:10.1182/hem.v22.1.202511
The emerging role of stem-cell transplantation for multiple myeloma and other plasma cell dyscrasias
Tsukada, N. (2025) · Japanese Journal of Transplantation and Cellular Therapy · doi:10.7889/tct-24-015
Immuntherapien des multiplen Myeloms
Kadel, S., & Rasche, L. (2025) · Die Onkologie · doi:10.1007/s00761-024-01658-0
Phua, C. W. T., & McCulloch, S. (2025) · Canadian Hematology Today · doi:10.58931/cht.2025.4s0161
Myélome multiple : ce que le rhumatologue doit savoir en 2025
Belkhir, R. (2025) · Revue du Rhumatisme · doi:10.1016/j.rhum.2025.01.022
Systchenko, T., Nsiala, L., Bobin, A., Gardeney, H., Motard, C., Olivier, G., Borde, F., Corby, A., Roul, C., Fleck, E., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5112748
Self-citationTherapie des multiplen Myeloms – was ist neu und was bleibt?
Kortüm, K. M., Waldschmidt, J. M., & Einsele, H. (2025) · Die Onkologie · doi:10.1007/s00761-024-01675-z
Self-citationCrusoé, E. D. Q., dos Santos, J. S. L. R., Santos, J. D. A., Santos, H. H. D. M., Santos, A. D. S., Lucas, L. F., Requião, C., Freire, P. N. C., de Jesus, A. A., Almeida, A. D. M., et al. (2025) · Blood Neoplasia · doi:10.1016/j.bneo.2025.100081
“20 Triplet regimens can be very expensive depending on the agents used, and in countries facing more severe resource limitation and reduced access to novel agents, alternative induction regimens are of great interest.”
Radhi, M., Yusuf, D. A., AlSaffar, G. M., & Toorani, Z. A. (2025) · Cureus · doi:10.7759/cureus.80068 · Cited by 1
“Following the autologous stem cell transplant, maintenance therapy is initiated [23].”
Gaspar, E., Yi, I., & Bar, N. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2476656
“Additionally, our patients were slightly older with a median age of 66 compared with other trials where median age ranged from 59–63, which may be a risk factor for PN [3,4, 7,9,13].”
Influential
Metadata
- Authors
- Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., Perrot, A., Cavo, M., Belotti, A., Broijl, A., Gay, F., Mina, R., Nijhof, I. S., van de Donk, N. W. C. J., Katodritou, E., Schjesvold, F., Sureda Balari, A., Rosiñol, L., Delforge, M., Roeloffzen, W., Silzle, T., Vangsted, A., Einsele, H., Spencer, A., Hajek, R., Jurczyszyn, A., Lonergan, S., Ahmadi, T., Liu, Y., Wang, J., Vieyra, D., van Brummelen, E. M. J., Vanquickelberghe, V., Sitthi-Amorn, A., de Boer, C. J., Carson, R., Rodriguez-Otero, P., Bladé, J., & Moreau, P.
- Affiliations
- University Medical Center Groningen (NL)
- The University of Sydney (AU)
- From the Department of Hematology, Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) — all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) — both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi ...
- Oslo University Hospital (NO)
- Jagiellonian University (PL)
- ORCID
- Sonneveld, Pieter
- Dimopoulos, Meletios A.
- Boccadoro, Mario
- Quach, Hang
- Ho, P. Joy
- Hulin, Cyrille
- Antonioli, Elisabetta
- Leleu, Xavier
- Mangiacavalli, Silvia
- Perrot, Aurore
- Belotti, Angelo
- Broijl, Annemiek
- Gay, Francesca
- Mina, Roberto
- Katodritou, Eirini
- Schjesvold, Fredrik
- Rosiñol, Laura
- Delforge, Michel
- Roeloffzen, Wilfried
- Silzle, Tobias
- Vangsted, Annette
- Einsele, Hermann
- Spencer, Andrew
- Jurczyszyn, Artur
- Ahmadi, Tahamtan
- Liu, Yanfang
- Wang, Jianping
- Sitthi-Amorn, Anna
- Bladé, Joan
- Moreau, Philippe
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-01-25
- Volume
- 390
- Issue
- 4
- Pages
- 301-313
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4389606680
- Cited by
- 599
- References
- 23
- Citations by year
- 2026: 198 · 2025: 252 · 2024: 145
- FWCI
- 123.04
- Type
- journal article
- Language
- en
- Open access
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- European Myeloma Network in collaboration with Janssen Research & Development, LLC
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- multiple myeloma, daratumumab, bortezomib, lenalidomide, dexamethasone, subcutaneous daratumumab, CD38, newly diagnosed multiple myeloma, progression-free survival, minimal residual disease, complete response, lenalidomide maintenance, neutropenia
- MeSH terms
- Bortezomib, Lenalidomide, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Humans, Membrane Glycoproteins, Multiple Myeloma, Disease Progression, ADP-ribosyl Cyclase 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


